Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 66, Issue 2, Pages 335-343
Publisher
Wiley
Online
2016-11-05
DOI
10.1002/hep.28916
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients
- (2016) W. Ray Kim et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load
- (2015) Dong Hyun Sinn et al. HEPATOLOGY
- Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis
- (2015) Jeong Won Jang et al. HEPATOLOGY
- AASLD guidelines for treatment of chronic hepatitis B
- (2015) Norah A. Terrault et al. HEPATOLOGY
- Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load
- (2015) Li-Bo Yan et al. Clinics and Research in Hepatology and Gastroenterology
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
- (2015) JOURNAL OF HEPATOLOGY
- Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
- (2014) Henry L.Y. Chan et al. GASTROENTEROLOGY
- Liver cirrhosis
- (2014) Emmanuel A Tsochatzis et al. LANCET
- Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
- (2013) A. K. Singal et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
- (2013) Grace Lai-Hung Wong et al. HEPATOLOGY
- Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?
- (2013) Morris Sherman HEPATOLOGY
- Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
- (2013) Stuart C. Gordon et al. HEPATOLOGY
- Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders
- (2012) Benjamin Yip et al. DIGESTIVE DISEASES AND SCIENCES
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
- (2012) Patrick Marcellin et al. LANCET
- Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
- (2011) Roeland Zoutendijk et al. HEPATOLOGY
- Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir
- (2011) C. Q. Pan et al. JOURNAL OF VIRAL HEPATITIS
- Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma
- (2010) Ju Dong Yang et al. Clinical Gastroenterology and Hepatology
- Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
- (2010) Ting-Tsung Chang et al. HEPATOLOGY
- Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)
- (2010) Kyu Sik Jung et al. HEPATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started